Acute Myeloid Leukemia and Myelodysplastic SyndromePhase 1NCT07283094Papers
FHD-286
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
83 Phase 1 studies recruiting right now, most recently updated first.
Open the Phase 2 page · a list of only those studies
Triangle is made by Triangle Health, Inc.
Leukemia, lymphoma, and myeloma83 studies
Acute Myeloid Leukemia and Myelodysplastic SyndromePhase 1NCT07283094Papers
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
EBV-Positive Hodgkin and Non-Hodgkin LymphomaPhase 1NCT01555892Papers
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
Relapsed/Refractory B-Cell Non-Hodgkin LymphomaPhase 1NCT06209619
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
Newly Diagnosed Acute Myeloid LeukemiaPhase 1NCT05558124
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
Relapsed or Refractory Large B-Cell LymphomaPhase 1NCT05755087
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
Relapsed/Refractory Acute Myeloid LeukemiaPhase 1/2NCT05580601
Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)
Non Hodgkin Lymphoma (NHL)Phase 1/2NCT04186520Papers
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Relapsed or Refractory Chronic Lymphocytic LeukemiaPhase 1/2NCT06644183
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Relapsed/Refractory Multiple MyelomaPhase 1NCT07093554
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
B-cell Acute Lymphoblastic LeukemiaPhase 1NCT06559189Papers
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
Acute Lymphoblastic Leukemia, AdultPhase 1/2NCT03676504Papers
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR